Completed PHASE3 INTERVENTIONAL NCT00191087

Duloxetine in the Treatment of Stress Urinary Incontinence.

Long-Term Monitoring of Safety in Subjects Treated With Duloxetine for Stress Urinary Incontinence.

Sponsor: Boehringer Ingelheim

Interventions Duloxetine

Updated 5 times since 2017 Last updated: Jan 24, 2007 Started: Apr 30, 2001 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00191087, this PHASE3 trial focuses on Urinary Incontinence, Stress and remains completed. Sponsored by Boehringer Ingelheim, it has been updated 5 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom